Cardiogeni PLC (LSE:CGNI) said on 28 October 2026 that it now expects to release its audited accounts for the year to 31 March 2026 in mid-November 2026, later than the second-half-of-October timing it gave earlier. Trading in its shares on the AQSE Growth Market remains suspended until the accounts are published.

What was announced

Cardiogeni, a UK clinical-stage biotechnology company traded on the AQSE Growth Market under the ticker CGNI, issued an update on the timing of its audited annual accounts for the financial year ended 31 March 2026.

The company said it has been "working closely with its auditors" to prepare the accounts for release. It now expects publication in mid-November 2026, "rather than in the second half of October 2026 as previously announced."

Trading in Cardiogeni's shares remains suspended pending publication. Once the accounts are released, the company intends to seek restoration of trading. It said further updates would be provided as appropriate.

How the timetable has moved

The deadline for publishing the audited accounts was 30 September 2026. On 1 October 2026 Cardiogeni announced that the accounts would not be published by that date and that trading in its shares would be temporarily suspended. At that point the company said it expected publication in the second half of October.

The latest update moves that expectation back by several weeks. On a reading of the two dates, if the accounts appear in mid-November as now expected, they would be published about six weeks after the original 30 September deadline, and the shares would have been suspended for roughly the same period. The company has not given an exact date.

What was not disclosed

The announcement is brief. Beyond saying it has been working closely with its auditors, the company gave no reason for the delay or for the further slippage. It did not name its auditors, give any financial figures for the year to 31 March 2026, or indicate whether the delay relates to any particular accounting issue. No comment from the board was included.

Cardiogeni (LSE:CGNI) describes itself as a UK clinical-stage biotechnology company founded by 2007 Nobel Laureate Sir Martin Evans, focused on developing and commercialising novel heart regeneration medicines. The update gave no news on its clinical or development programmes.

People and advisers

The announcement lists Dr Darrin M Disley as Executive Chairman and Ajan Reginald as Executive Officer. First Sentinel Corporate Finance is the company's corporate adviser, and SP Angel Corporate Finance is its corporate broker.

What to watch next

The key event is publication of the audited accounts for the year to 31 March 2026, now expected by the company in mid-November 2026. That will be the first opportunity to see the company's full-year financial position and any comments from the auditors. After publication, Cardiogeni has said it will seek to have trading in its shares restored. Any further change to the expected timing would be expected to come through a further update, which the company said it would provide as appropriate.